Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

In this study, a daily topical application of a 0.05% tretinoin solution effectively removed dark plugs and resolved symptoms of trichostasis spinulosa.

This study found that an anhydrous gel formulation containing sertaconazole nitrate effectively penetrated the stratum corneum for treating fungal infections without causing irritation.

In this study, a low concentration zinc sulphate solution was investigated for managing recurrent herpes simplex infections, but no new clinical results were reported.

This study reports that daily topical application of a 0.05% tretinoin solution can eliminate the hair plugs and symptoms associated with trichostasis spinulosa.

In this study, researchers assessed the physical-chemical and microbiological stability of various pharmaceutical ingredients in the vehicle TrichoSolTM, finding differing beyond-use dates for the compounds, such as 180 days for cetirizine hydrochloride, but only 90 days for progesterone at higher concentrations.

This study found that adherence to topical hydrocortisone in adults with atopic dermatitis was inconsistent and not significantly different across different medication vehicles, though disease severity improved markedly within 2 weeks.

This study found that the topically applied non-steroidal antiandrogen RU 58841 may reduce androgen-dependent skin conditions in a hamster model with minimal systemic effects.

This source describes clascoterone, a new topical treatment for acne vulgaris that blocks androgen receptors to reduce sebaceous gland activity and inflammation, offering a lower risk of systemic side effects compared to oral treatments.

This review discusses the use of topical immunotherapy for severe alopecia areata and resistant viral warts, highlighting diphencyprone's advantages and the need for careful handling to avoid staff sensitisation; it reports no new clinical results.

This study concluded that topical betamethasone valerate lotion is more effective than 15% lactic acid solution for managing multiple patchy alopecia areata over a 12-week period in a sample of 50 patients.

This study found that betamethasone valerate in a foam vehicle has comparable total coverage to traditional topical corticosteroid vehicles, despite less coverage per unit of foam.

This study in Jordan found that topical corticosteroid use is common and often involves creams obtained without prescriptions, with only 61.3% of users aware of potential side effects, highlighting a need for better public education and regulation to prevent misuse.

This study evaluated the stability of multiple active ingredients in TrichoSol™ for use in alopecia treatments, finding varying stability durations at room temperature—up to 180 days for some ingredients—supporting its use as a compounding vehicle in personalized therapies.

This article reviews the clinical efficacy of Ruxolitinib cream for skin conditions, reporting significant improvements in atopic dermatitis and vitiligo, with minimal systemic absorption and a favorable safety profile, compared to placebo.

This study shows that many acne patients use topical steroids despite their association with various skin side effects, such as worsened acne, perioral dermatitis, and telangiectasias.

This abstract introduces TrichoFoam™, a new foaming vehicle for compounding pharmacies, designed to be a gentle, non-irritating option for alopecia treatment, acknowledging that current topical treatments are limited and oral products may cause adverse effects.

In this study on dogs, topical antimicrobial sprays with varying ingredient profiles showed different levels of S. pseudintermedius growth inhibition, maintaining activity for at least 10 days.

This paper reviews the challenges of treating alopecia areata affecting eyelashes and discusses the risks associated with traditional therapies; it reports no new clinical results.

This review discusses the use of contact sensitizers in topical immunotherapy for conditions like alopecia areata and viral warts, focusing on treatment methods, efficacy, and potential adverse effects, and reports no new clinical results.

This study found that 62% of acne patients used topical steroids, which were associated with several skin side effects like aggravation of lesions and perioral dermatitis.

This article discusses the potential of topical ruxolitinib as a treatment for alopecia universalis and acknowledges the need for alternatives to systemic JAK inhibitors due to the risk of serious side effects.

This source reports that clascoterone cream, a topical androgen receptor inhibitor, has shown effectiveness in treating facial acne vulgaris in patients 12 and older, with clinical trials indicating a favorable safety profile compared to systemic treatments, and potential for broader dermatological applications.

This report describes two cases where topical squaric acid dibutylester application in alopecia totalis patients led to severe pustular lesions, necessitating systemic prednisolone treatment.

This article discusses the challenges in treating hidradenitis suppurativa, highlighting that adalimumab is currently the only FDA-approved treatment, and reports no clinical results.

The document concludes that various topical medications are effective for skin conditions but often cause skin irritation as a side effect.

This article offers strategies for managing acne effectively and safely, emphasizing treatment optimization, patient tailoring, and addressing antimicrobial resistance, but reports no new clinical results.

This review discusses the use of contact sensitizers for topical immunotherapy in dermatological conditions such as alopecia areata and viral warts, but it reports no new clinical findings.

This article discusses the potency grading of steroid skin creams and highlights that very potent or potent steroids (grades I and II) can cause significant side effects, especially in children.